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Abstract
Nausea, vomiting, and renal injury are the common adverse effects associated with 
cisplatin. Cisplatin is excreted via the multidrug and toxin release (MATE) transporter, 
and the involvement of the MATE transporter in cisplatin- induced kidney injury has 
been reported. The MATE transporter is also involved in the excretion of ondanse-
tron, but the effects of 5- HT3 receptor antagonists used clinically for cisplatin- induced 
renal injury have not been elucidated. Therefore, the aim of this study was to investi-
gate the effects of 5- HT3 receptor antagonists in a mouse model of cisplatin- induced 
kidney injury and to validate the results using medical big data analysis of more than 
1.4 million reports and a survey of 3000 hospital medical records. The concomitant 
use of a first- generation 5- HT3 receptor antagonist (ondansetron, granisetron, or ra-
mosetron) significantly increased cisplatin accumulation in the kidneys and worsened 
renal damage. Conversely, the concomitant use of palonosetron had no effect on renal 
function compared with the use of cisplatin alone. Furthermore, an analysis of data 
from the US Food and Drug Administration Adverse Event Reporting System and 
retrospective medical records revealed that the combination treatment of cisplatin and 
a first- generation 5- HT3 receptor antagonist significantly increased the number of re-
ported renal adverse events compared with the combination treatment of cisplatin and 
a second- generation 5- HT3 receptor antagonist. These results suggest that compared 
with the first- generation antagonists, second- generation 5- HT3 receptor antagonists 
do not worsen cisplatin- induced acute kidney injury. The findings should be validated 
in a prospective controlled trial before implementation in clinical practice.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
The involvement of the multidrug and toxin release (MATE) transporter in cisplatin- 
induced kidney injury has been reported. The MATE transporter is involved in the 
excretion of not only cisplatin but also ondansetron, a 5- HT3 receptor antagonist used 
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as an antiemetic; however, the effects of 5- HT3 receptor antagonists used clinically 
for cisplatin- induced renal injury have not been elucidated.
WHAT QUESTION DID THIS STUDY ADDRESS?
The aim of this study was to investigate the effects of 5- HT3 receptor antagonists in 
a mouse model of cisplatin- induced kidney injury and to validate the results using 
medical big data analysis of more than 1.4 million reports and a survey of 3000 hos-
pital medical records.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
The results suggest that compared with the first- generation antagonists, second- 
generation 5- HT3 receptor antagonists do not worsen cisplatin- induced acute kidney 
injury.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
Promoting the use of second- generation 5- HT3 receptor antagonists is expected to 
reduce the number of patients who develop cisplatin- induced renal damage.
INTRODUCTION
Cisplatin, a platinum- based anticancer agent, is a key drug 
in various regimens. However, the adverse effects associ-
ated with cisplatin are often problematic in clinical practice, 
and they include renal impairment, hearing impairment, 
nausea, vomiting, and bone marrow suppression.1 Renal 
impairment, a dose- limiting toxicity of cisplatin, occurs in 
approximately one- third of patients treated with cisplatin. It 
can cause irreversible damage, thereby reducing the quality 
of life of patients and necessitating cisplatin dosage reduc-
tion, if treatment for renal impairment is not administered.2 
Therefore, it is important to ensure that the renal function of 
patients does not worsen during cisplatin administration to 
maintain treatment intensity. Hydration methods are strongly 
recommended in the guidelines for renal damage treatment 
during anticancer therapy.3 Studies have suggested that this 
approach reduces the frequency of renal damage.4 However, 
despite prophylactic treatment use, several patients receiv-
ing cisplatin experience a decline in renal function.5 There 
are no clinically effective therapies for the prophylaxis or 
treatment of cisplatin- induced renal injury, despite the com-
pletion of various studies in this regard.1,5,6 Cisplatin is a 
renally excreted drug, and more than 90% of the drug is ex-
creted in the urine over 24 h after intravenous injection.7 The 
concentration of cisplatin in the kidneys is approximately 
five- fold higher than that in the serum and the accumula-
tion of cisplatin in the kidneys significantly contributes to 
nephrotoxicity.8– 10 Cisplatin- induced kidney injuries include 
severe damage to tubular cells, and nephrotoxicity originates 
in the proximal tubules.11 Preclinical studies have eluci-
dated the mechanisms underlying cisplatin- induced kidney 
injury.5– 7 Two transporters implicated in the development of 
cisplatin- induced kidney injury are organic cation transporter 
2 (OCT2), located on the basement membrane side of the 
proximal renal tubules, and multidrug and toxin extrusion 
(MATE) protein, located on the brush border membrane side 
of the proximal renal tubules. Cisplatin is taken up from the 
blood into the proximal renal tubular cells via OCT2, and 
then excreted into the tubules from the proximal renal tubular 
cells via MATE.12– 14
The cisplatin transport activity of MATE is considerably 
lower than that of OCT2, and this difference leads to cisplatin 
accumulation in the proximal renal tubules.15,16 Therefore, the 
inhibition of OCT2 expression may reduce cisplatin accumula-
tion in the tubules, whereas the inhibition of MATE expression 
may increase cisplatin accumulation. Notably, cimetidine, a 
substrate of OCT2, has been reported to limit cisplatin- induced 
renal damage,17 whereas the MATE inhibitor pyrimethamine 
has been reported to exacerbate renal damage.15
Cisplatin is designated as highly emetogenic in the 
Guidelines for the Proper Use of Antiemetic Drugs, with 
nausea and vomiting occurring in more than 90% of pa-
tients.18 Nausea and vomiting can be controlled with the ap-
propriate use of antiemetics. Because nausea and vomiting 
associated with chemotherapy are caused by the combined 
stimulation of 5- HT₃ receptors in the gastrointestinal tract 
and NK- 1 receptors in the chemoreceptor trigger zone, these 
receptor antagonists and steroids are indicated as antiemetic 
agents. Notably, a three- drug combination, comprising an 
NK- 1 receptor antagonist, a 5- HT₃ receptor antagonist, and a 
steroid, has been recommended for use with cisplatin18 and 
incorporated as a supportive therapy in various regimens. 
The 5- HT₃ receptor antagonists include the first- generation 
agents, ondansetron and granisetron, and second- generation 
agent, palonosetron, and each regimen is used differently. 
The 5- HT₃ receptor antagonists have been reported to be sub-
strates for OCT2 and MATE.19,20 Furthermore, a preclinical 
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study using a mouse model of cisplatin- induced kidney in-
jury demonstrated that ondansetron, a first- generation drug, 
may exacerbate cisplatin- induced kidney injury by inhibiting 
MATE.16 However, the effects of 5- HT₃ receptor antagonists 
used clinically to prevent cisplatin- induced nausea and vom-
iting on cisplatin- induced kidney injury remain unknown. 
Therefore, here, we investigated the effects of various 5- HT₃ 
receptor antagonists in a mouse model of cisplatin- induced 
kidney injury and validated the results obtained using data 
from retrospective clinical trials and from the analysis of 
medical data.
MATERIALS AND METHODS
Animal model of cisplatin- induced 
nephrotoxicity
All experimental procedures were performed in accordance 
with the guidelines of the Animal Research Committee of 
Tokushima University Graduate School, and the protocol was 
approved by the Institutional Review Board of Tokushima 
University Graduate School for Animal Protection (Permit 
Number: T30- 85). Nine- to- ten- week- old C57BL/6  J mice 
(weighing 24– 27  g) were purchased from Nippon CLEA 
(Tokyo, Japan) and maintained with ad libitum access to 
water and food (type NMF; Oriental yeast, Tokyo, Japan). 
The relative humidity in the breeding room was set at 
50% ± 10% and the room temperature was 26°C ± 1°C, with 
a 12- h light/dark cycle (lights on at 8:00 a.m., lights off at 
8:00 p.m.). The mice were randomly divided into six groups 
(n = 7– 9 per group): vehicle- injected, cisplatin- injected, and 
first- generation 5- HT3 receptor antagonists (ondansetron 
[1  mg/kg], granisetron [30  mg/kg], or ramosetron [1  mg/
kg]) or second- generation 5- HT3 receptor antagonists (palo-
nosetron [1.5 mg/kg]) administered to the cisplatin- injected 
group. The mice were intraperitoneally injected with cispl-
atin (15 mg/kg) or vehicle. Thirty minutes before cisplatin 
injection, the mice were administered various 5- HT3 recep-
tor antagonists intraperitoneally, including first- or second- 
generation 5- HT3 receptor antagonists, or vehicle. At 4, 24, 
and 72 h after cisplatin injection, the mice were euthanized 
by an overdose of anesthesia, and samples were collected for 
the subsequent analysis. The doses were based on those used 
as antiemetic agents in animal models.21– 25
Determination of blood and urine creatinine and 
blood urea nitrogen levels
Blood urea nitrogen (BUN), serum creatinine (serum Cr), 
and urine creatinine (urine Cr) levels in the serum and 
urine samples were determined by Oriental Yeast Industries 
(Shiga, Japan). Creatinine clearance (CrCL) was calculated 
as follows:
CrCL (ml/min/kg) = urine volume (ml/min/kg) × urine Cr 
concentration (mg/dl) / serum Cr concentration (mg/dl).
Real- time polymerase chain reaction using the 
kidney tissues from mice with cisplatin- induced 
kidney injury
The kidneys were collected from mice with cisplatin- 
induced kidney injury. RNA was extracted from the kidney 
samples using an RNA extraction solution (NIPPON GENE) 
according to the manufacturer’s instructions. The cDNA 
was reverse transcribed using the PrimeScript RT Reagent 
kit (Takara Bio) and a polymerase chain reaction (PCR) 
Thermal Cycler Dice (Takara Bio). The cDNA from each 
sample was mixed with forward and reverse primers and 
THUNDERBIRD SYBR qPCR Mix (Toyobo); PCR was 
performed using an Applied Biosystems StepOnePlus ma-
chine (Applied Biosystems). Fold changes in gene expres-
sion relative to those of the control group were evaluated 
using mouse glyceraldehyde 3- phosphate dehydrogenase 
as the internal standard. The primer sets used for PCR are 
shown in Table S1.
Histological analysis
Renal tubular injury was assessed as previously described.21 
Briefly, the kidney samples were fixed with 4% paraformal-
dehyde and embedded in paraffin. The samples were cut into 
4- μm sections, which were then stained with hematoxylin 
and eosin. Tubular damage was scored blindly by 3 or more 
individuals other than the experimenter, according to the per-
centage of damage (tubular necrosis, brush border loss, cast 
formation, tubular dilation, and tubular degeneration), as fol-
lows: 0, normal; 1, less than 25%; 2, 25%– 50%; 3, 50%– 75%; 
and 4, greater than 75%. Ten random microscopic fields per 
kidney section were used for quantification using the BX53 
microscope (Olympus).
Determination of platinum concentration
To determine the concentration of platinum, 20  mg of 
the kidney sample or 20 μl of whole blood was incubated 
with 200 μl of 60% nitric acid (Wako) for 1 h at 95°C. The 
lysates were centrifuged at 5000 g for 10 min, and 50 μl of 
the supernatant was diluted with nitric acid. Platinum con-
centration was assessed using a polarized Zeeman atomic 
absorption spectrophotometer (Model Z- 5710; Hitachi 
High- Technologies Co.). The absolute concentration of 
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platinum in the kidneys and whole blood was determined 
using a calibration curve.
Uptake study in HEK293 cells stably 
expressing hMATEs
Human embryo kidney cells were obtained from the Japanese 
Collection of Research Bioresources Cell Bank (Osaka, 
Japan). The cells stably expressing hMATE1 (2.0 × 105 cells/
well) were grown in 96- well plates for 24 h and used in the 
DAPI- update assay. The cells were preincubated with 0.1 ml 
of DAPI- free uptake buffer (130 mM KCl, 2 mM K2HPO4, 
1.2 mM MgSO4, 1.0 mM CaCl2, 5 mM glucose, and 20 mM 
HEPES; pH 8.0) for 10  min. The uptake assay was initi-
ated by replacing the DAPI- free uptake buffer with a buffer 
containing DAPI (0.5 μM) (0.1 ml) for 10 min. The optimal 
experimental conditions were determined after preliminary 
experiments based on a previous study.26 All procedures were 
performed at 37°C. The reactions were terminated by adding 
ice- cold DAPI- free uptake buffer (0.1 ml), and the cells were 
washed twice with 0.1  ml of the same buffer. Thereafter, 
each well was filled with 0.1 ml of ice- cold DAPI- free uptake 
buffer, and the intensity of DAPI fluorescence was measured 
using a fluorescence plate reader (SpectraMaxi3; Molecular 
Devices; 345 nm excitation wavelength and 455 nm emission 
wavelength) to evaluate uptake. Cellular protein content was 
determined as described previously27 using bovine serum 
albumin as the standard. The uptake assay was also per-
formed in mock cells, which were transfected with an empty 
pcDNA5.1 vector, to determine nonspecific uptake. The half- 
maximal inhibitory concentration (IC50) was calculated using 
the probit analysis with SPSS (SPSS Inc.).
Assessing the effects of concomitant drugs
From January 2004 to June 2020, 14,524,065 spontaneous 
adverse event reports were submitted to the US Food and 
Drug Administration’s (FDA) Adverse Event Reporting 
System (FAERS), and they were downloaded from the FDA 
website.28 Duplicate data were excluded in accordance with 
the FDA recommendations, and the remaining 12,192,072 
reports were used in the analysis. SQLite was used to process 
the data, and R version 3.2.1 (R Foundation for Statistical 
Computing) was used for statistical analyses. Acute renal 
failure was defined using 47 terms of “acute renal failure 
(SMQ 20000003)” excluding neonatal and pediatric diseases 
(Table S2) according to Medical Dictionary for Regulatory 
Activities (MedDRA) version 23.1.
The risk of adverse events was assessed using the reporting 
odds ratio (ROR) and 95% confidence interval (CI). Patients 
who received cisplatin were classified into four groups: (1) 
patients who used drug A and reported acute renal failure; (2) 
patients who used drug A and did not report acute renal fail-
ure; (3) patients who did not use drug A and reported acute 
renal failure; and (4) patients who did not use drug A and did 
not report acute renal failure. Based on the following equa-
tion, the ROR and 95% CI were calculated.
All tests were two- tailed, and results with p values less 
than 0.05 were considered statistically significant.
Study design and population
We performed a retrospective case- control study in patients 
who received cisplatin at Tokushima University Hospital, a 
tertiary academic teaching hospital in Tokushima, Japan, be-
tween January 1, 2007, and December 31, 2019, under the 
approval of the Ethics Committee of Tokushima University 
Hospital (reference number 3820). This study was conducted 
according to the principles set forth in the Declaration of 
Helsinki. Because the present study was retrospective in na-
ture and used existing information, an opt- out option was dis-
played on the institution website as a surrogate for informed 
consent for eligible patients according to the Japanese 
Governmental guidelines.29 Patients were included if they 
had received a single dose of cisplatin greater than or equal to 
60 mg/m2 during one course of treatment, according to previ-
ous studies.30,31 Patients were excluded if they were under 
18  years of age, registered in an industry- initiated clinical 
trial, or had insufficient renal function (baseline serum creati-
nine [SCr] level of ≥1.5 mg/dl and/or estimated glomerular 
filtration rate [eGFR] of <60 ml/min/1.73 m2).32,33
Data collection and definitions
We collected baseline data related to physiological conditions, 
laboratory results, concomitant medication use, and disease his-
tory upon the initiation of cisplatin using electronic medical re-
cords from Tokushima University Hospital. Cisplatin- induced 
nephrotoxicity (CIN) was defined as an increase in the SCr 
level by greater than or equal to 0.3 mg/dl (26.5 μmol/L) or 50% 
of the baseline level at 7 days after cisplatin administration.34,35 
Data on the proportion of patients using other antiemetic agents, 
such as NK1R antagonists, olanzapine, were not obtained be-
cause these drugs do not affect renal function in patients with an 
eGFR of greater than or equal to 60 ml/min/1.73 m2.36– 39
ROR =
AD
BC
95% CI = exp(ln ROR ± 1.96
√
1
A
+
1
B
+
1
C
+
1
D
)
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The eGFR was calculated as follows40:
eGFR (ml/min/1.73  m2)  =  194  ×  serum creatinine - 
1.094 × age - 0.287 × 0.739 (if female).
Propensity score matching analysis
As patients in this retrospective case- control study were 
not randomized as patients treated with the first or second- 
generation antiemetic agents, propensity score matching 
(PSM) was performed to decrease the variability between 
treatment cohorts. Fourteen factors (sex, age, body surface 
area [BSA], eGFR, cisplatin dosing/BSA, serum creatinine, 
aspartate aminotransferase, alanine aminotransferase, total 
bilirubin, serum albumin, and number of patients concomi-
tantly using magnesium sulfate and with chronic heart dis-
ease, hypertension, and diabetes mellitus) were selected as 
factors associated CIN and/or kidney injury or were deemed 
a priori to be important demographic characteristics for use 
in a logistic regression model, which was used to calculate 
propensity scores.41– 43 A 1:1 PSM analysis was performed 
using the nearest neighbor matching method with a caliper of 
0.20 to reduce the potential bias of patient characteristics.44 
Matching was performed without a replacement treatment, 
and cases not meeting the matching criteria were excluded.
Statistical analysis
Differences between groups were analyzed using the para-
metric unpaired t- test or nonparametric Mann– Whitney U 
test, as applicable. Categorical variables were compared 
using Fisher’s exact test or χ2 test. Results with a p value 
of less than 0.05 were considered statistically significant. 
Statistical analysis of data of the retrospective case- control 
study was performed using JMP version 15.0 software (SAS 
Institute Inc.). For comparisons among three or more groups, 
a one- way analysis of variance was performed. Tukey’s test 
was also performed as a post hoc analysis. R version 3.2.1 for 
Windows was used for statistical analyses, and results with a 
two- tailed p value of less than 0.05 were considered statisti-
cally significant.
RESULTS
Effects of 5- HT₃ receptor antagonists on 
cisplatin- induced kidney injury in mice
Cisplatin- treated mice presented a decrease in body weight, 
but no change in kidney weight (Table 1). Cisplatin- treated 
mice exhibited KIM- 1 and Lcn2 mRNA expression, mark-
ers of renal tubular damage, presented elevated plasma BUN, 
and showed a significant decrease in CrCL, which indicated 
kidney damage (Table  1, Figure  1h,i). Cisplatin in combi-
nation with ondansetron, granisetron, or ramosetron exacer-
bated cisplatin- induced kidney damage (Table 1, Figure 1h,i); 
whereas, combination treatment with palonosetron did not 
exacerbate cisplatin- induced renal damage.
Histological evaluation
Cisplatin treatment was associated with the degeneration 
and disruption of renal tissue, including nuclear loss, proxi-
mal tubular cell emptying, and tubular dilation. Mice treated 
with the first- generation 5- HT₃ receptor antagonists pre-
sented more extensive damage, such as tubular dilation and 
tubular cell necrosis, than mice treated with cisplatin alone. 
However, there was no difference between the groups that 
received combination treatment of cisplatin and palonosetron 
and cisplatin alone (Figure 1g).
The first- generation 5- HT₃ receptor antagonist group had 
a significantly higher score than the cisplatin only group. The 
T A B L E  1  Body weight, kidney weight, and renal function in vehicle- treated mice and cisplatin- treated mice with or without 5- HT₃ receptor 
antagonists
Vehicle CDDP CDDP + ond CDDP + gra
CDDP 
+ ramo
CDDP 
+ palo
Initial body weight 
(g)
26.1 ± 0.6 26.4 ± 0.7 26.2 ± 0.3 28.4 ± 0.4 27.6 ± 1.0 26.5 ± 0.3
Post body weight (g) 25.2 ± 0.5 20.7 ± 0.5† 20.3 ± 0.3† 21.9 ± 0.6† 21.1 ± 0.9† 20.9 ± 0.7†
Kidney weight (mg) 189.0 ± 7.0 156.9 ± 4.4 171.9 ± 8.0 194.7 ± 5.1 181.0 ± 7.4 173.6 ± 5.0
Urine volume (ml) 1.60 ± 0.25 0.95 ± 0.10† 0.85 ± 0.17† 0.92 ± 0.17† 0.85 ± 0.14† 0.93 ± 0.10†
BUN (mg/dl) 21.22 ± 0.69 81.86 ± 5.47† 180.23 ± 21.56 **## 123.80 ± 13.42 123.59 ± 17.6 90.80 ± 19.04
CrCL (ml/min/kg) 10.89 ± 1.05 4.94 ± 0.70† 1.29 ± 0.43 **## 1.75 ± 0.20 *# 1.58 ± 0.20 *# 4.83 ± 0.92
Note: Data are presented as mean ± SEM.
Abbreviations: BUN, blood urea nitrogen; CrCL, creatinine clearance; CDDP, cisplatin; gra, granisetron; ond, ondansetron; palo, palonosetron; ramo, ramosetron.
†p < 0.05 versus vehicle mice, *p < 0.05 and **p < 0.01 versus CDDP mice. #p < 0.05 and ##p < 0.01 versus CDDP + palonosetron mice; n = 7– 9 in each group.
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score for combination treatment with palonosetron was simi-
lar to that for cisplatin alone (Figure 1g).
Effects of 5- HT3 receptor inhibitors 
on the platinum concentration in the whole 
blood and kidneys
The renal platinum concentration significantly increased in mice 
treated with ondansetron, granisetron, or ramosetron at 4 h after 
cisplatin administration (Figure 2a). In contrast, palonosetron 
administration had no effect on the renal platinum concentra-
tion (Figure 2a). There was no difference in the platinum con-
centration in whole blood at 4 h after cisplatin administration 
in all groups (Figure 2b). At 24 h after cisplatin administration, 
renal accumulation of cisplatin (CDDP only, 14.40 ± 2.74 μg/g, 
n = 6) was less than half of that at 4 h, and no effect of concomi-
tant medication was observed (data not shown). These results 
suggest that the first- generation 5- HT3 receptor inhibitors may 
increase platinum accumulation in the kidneys.
Uptake study in HEK293 cells stably 
expressing hMATEs
The cis- inhibition analysis with DAPI revealed that the first- 
generation inhibitors had an IC50 equal to or lower than that 
of cimetidine, a typical MATE inhibitor. The first- generation 
inhibitors were found to have a lower IC50 than the second- 
generation inhibitors (Table 2, Figure S1).
F I G U R E  1  Effects of 5- HT₃ receptor antagonists on cisplatin- induced nephrotoxicity. (a– f) Representative hematoxylin and eosin staining 
(H&E) of the kidney section of the control mice, cisplatin (CDDP)- injected mice with vehicle or a 5- HT₃ receptor antagonist. (a) vehicle, (b) 
CDDP, (c) CDDP + ondansetron, (d) CDDP + granisetron, (e) CDDP + ramosetron, (f) CDDP + palonosetron. (g) Quantitative analysis of renal 
damage scores. Values are expressed as mean ± SEM. ond; ondansetron, gra; granisetron, ramo; ramosetron, palo; palonosetron, †p < 0.05 vs. 
vehicle mice, **p < 0.01 versus CDDP mice. ##p < 0.01 versus CDDP + palonosetron mice; n = 7– 9 in each group. (h), (i) The mRNA expression 
levels of kidney injury markers (Kim- 1 [h] and Lcn- 2 [i]) in the kidneys of mice in each group. Values are expressed as mean ± SEM. ond; 
ondansetron, gra; granisetron, ramo; ramosetron, palo; palonosetron, †p < 0.05 versus vehicle mice, **p < 0.01 versus CDDP mice. ##p < 0.01 
versus CDDP + palonosetron mice; n = 7– 9 in each group
(a) (b) (c)
(d) (e) (f)
(g)
(i)(h)
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FAERS analysis results
Among 14,524,065 spontaneous adverse event reports submit-
ted from January 2004 to June 2020, 44,678 cases involved cis-
platin administration. Based on these reports, the ROR for acute 
renal failure was compared among cases reporting combination 
treatment with the first- or second- generation 5- HT₃ receptor 
antagonists. In total, 8.0% of the patients who received cispl-
atin reported acute renal failure. The OR of the first- generation 
5- HT₃ receptor antagonists in combination with cisplatin was 
1.26 (95% CI: 1.140– 1.398), and that of the second- generation 
5- HT₃ receptor antagonists was 0.79 (95% CI: 0.607– 1.02). 
The combination of cisplatin with the first- generation 5- HT₃ 
receptor antagonists significantly increased the reported OR for 
cisplatin- related nephropathy (p < 0.01; Table 3).
Patient characteristics
Among 2664 patients treated with CDDP, between January 
1, 2007 and December 31, 2019, 53 patients met the inclu-
sion criteria but had insufficient clinical data to allow the 
evaluation of patient characteristics listed in Table 1; thus, 
431 fulfilled the inclusion and exclusion criteria and were 
enrolled. CIN occurred in 40 of the 431 enrolled patients 
(Figure 3). Among these, 126 patients received a concomi-
tant first- generation antiemetic (first group) and 305 received 
a concomitant second- generation antiemetic (second group). 
There was no significant difference in the incidence of CIN 
between the groups (first group, 11.9%; second group, 8.2%; 
Table  4). Conversely, there was a significant difference in 
age, eGFR, SCr, serum albumin, and proportion of patients 
concomitantly using magnesium sulfate between the groups.
Propensity score- adjusted results
The area under the curve of the propensity score for second- 
generation antiemetic treatment, with 14 covariates, was 
0.812. We obtained 111 pairs by matching the propensity 
score at a caliper value of 0.2. The significant differences in 
age, eGFR, and percentage of patients using Mg sulfate that 
affected CIN development observed in the 111 pairs before 
matching were eliminated in the pairs after matching. After 
the 1:1 PSM analysis, CIN in the first group (15/111, 13.5%) 
was significantly lower than that in the second group (6/111, 
5.4%) in the 111 matched pairs. Patients using antiemetics 
with different pharmacokinetics, such as hepatic metabolism 
and renal excretion, were included. There were no significant 
differences in hepatic and renal functions between the groups 
after matching the 111 pairs. The proportion of patients who 
received steroids to improve renal function did not differ be-
tween the groups in the 111 pairs after PSM matching (first 
group, 109/111, 98.2%; second group, 111/111, 100.0%, not 
significant). There was no significant difference in other pa-
tient characteristics, except for CIN incidence among the 111 
F I G U R E  2  Platinum content in the kidney (a) and whole blood (b) at 4 h after cisplatin (CDDP) treatment. Data are expressed as 
mean ± SEM. ond; ondansetron, gra; granisetron, ramo; ramosetron, palo; palonosetron, **p < 0.01 versus CDDP mice. ##p < 0.01 versus  
CDDP +palonosetron mice, N.S.: not significant; n = 7– 9 in each group
(a) (b)
T A B L E  2  IC50 value of 5- HT3 receptor antagonists for hMATE1
Drug IC50 (µM)
Ondansetron 0.75 ± 0.10
Granisetron 24.70 ± 4.81
Ramosetron 4.42 ± 1.03
Palonosetron 55.79 ± 6.13
Cimetidine 17.94 ± 4.71
Note: Values are expressed as mean ± SEM.
Abbreviation: IC50, half- maximal inhibitory concentration.
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matched pairs (Table 4). The PSM analysis indicated the ef-
ficacy of second- generation antiemetic drugs for CIN.
DISCUSSION
Our results show that the first- generation 5- HT₃ receptor an-
tagonists exacerbate cisplatin- induced kidney injury by in-
creasing cisplatin accumulation in the kidneys. Conversely, 
the second- generation 5- HT₃ receptor antagonists do not 
adversely affect the kidneys. The results indicate that the 
higher inhibitory effect of the first- generation 5- HT₃ receptor 
antagonists on MATE affects the increase in cisplatin accu-
mulation in the kidneys in response to these agents. A ret-
rospective analysis of reports in an adverse event- reporting 
database revealed a difference in the effects between the 
first- and second- generation 5- HT₃ receptor antagonists on 
cisplatin- induced kidney injury. A retrospective chart review 
of clinical patient data suggested that patients receiving the 
second- generation 5- HT₃ receptor antagonists may be at a 
lower risk of exacerbation of cisplatin- induced kidney injury 
than those receiving the first- generation drugs. Therefore, the 
second- generation 5- HT₃ receptor antagonists may be use-
ful as antiemetic agents as they do not exacerbate cisplatin- 
induced kidney injury.
Considerable progress has been made in cancer treatment. 
New anticancer agents with novel action mechanisms, such as 
tyrosine kinase inhibitors and immune checkpoint inhibitors, 
have been developed and used in clinical practice. However, 
several anticancer therapies with proven effectiveness con-
tinue to be used, including cisplatin, a platinum- based agent 
used in chemotherapy for various malignant solid tumors. 
Renal impairment is a dose- limiting toxicity of cisplatin and 
is a challenge to manage in clinical practice. Despite several 
studies, there are no clinically effective drugs for the preven-
tion and treatment of cisplatin- induced renal impairment; 
therefore, it is important to ensure that the renal function does 
not worsen during cisplatin treatment in order to maintain 
treatment intensity. Cisplatin is classified as a drug with a 
high emetogenic risk, and guidelines recommend the con-
comitant use of antiemetic agents. Previous studies in mouse 
models have reported that ondansetron exacerbates cisplatin- 
induced kidney injury. Therefore, 5- HT₃ receptor antagonists 
currently used in clinical practice may affect the incidence of 
T A B L E  3  Effect of 5- HT₃ receptor antagonists on the occurrence of cisplatin- induced ARF using the FAERS data analysis
Drug
ARF (%) without the 
drug
ARF (%) with the 
drug ROR (95% CI) p value
First- generation 5- HT₃ receptor antagonist
a 9.66% (3952/40899) 12.20% (461/3779) 1.26 (1.140– 1.398) <0.001c 
Second- generation 5- HT₃ receptor antagonist
b 9.92% (4350/43870) 7.80% (63/808) 0.79 (0.607– 1.018) 0.072c 
Abbreviations: ARF, acute renal failure; CI, confidence interval; FAERS, US Food and Drug Administration’s Adverse Event Reporting System; ROR, reporting odds 
ratio.
aOndansetron, Granisetron, and Ramosetron.
bPalonosetron.
cFisher’s exact test.
F I G U R E  3  Flow chart of patient 
selection. AKI, acute kidney injury
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cisplatin- induced renal injury. In a mouse model of cisplatin- 
induced renal injury, combination treatment with cisplatin 
and a first- generation 5- HT₃ receptor antagonist exacerbated 
renal damage. Histological evaluation of the renal sections 
revealed extensive proximal tubular cell necrosis.
To determine the cause of cisplatin- induced renal dam-
age exacerbated by the concomitant use of first- generation 
5- HT₃ receptor antagonists, we measured cisplatin accumu-
lation in the kidneys at 4 or 8 h after cisplatin administration. 
The concomitant use of a first- generation 5- HT₃ receptor 
antagonist significantly increased the renal cisplatin accu-
mulation; however, there was no difference in accumulation 
between animals that received combination therapy with 
palonosetron and those that received cisplatin monotherapy. 
Combination treatment with first- and second- generation 
agents did not affect the blood levels of cisplatin. Thus, the 
first- generation 5- HT₃ receptor antagonists altered cispla-
tin accumulation in the kidneys without affecting cisplatin 
pharmacokinetics.
The excretion of cisplatin from renal tubular cells is 
mediated by MATE1, which has been reported to be in-
volved in the CIN development.45 Ondansetron is a MATE 
transporter inhibitor.46,47 Ondansetron inhibited MATE and 
exacerbated cisplatin- induced kidney injury in mice.16 Li 
et al.16 showed that ondansetron inhibits MATE activity in 
vitro and increases the blood concentration and renal ac-
cumulation of metformin, a substrate of MATE transport-
ers, in vivo, suggesting a correlation between the inhibition 
of MATE transporters and inhibition of renal excretion of 
MATE substrates. It has also been reported that there is 
an association between transporter inhibitory activity, as 
determined in vitro, and clinical symptoms.48 Thus, a com-
parison of the MATE inhibitory activity of various 5- HT₃ 
receptor antagonists revealed that the second- generation 
inhibitor palonosetron had weaker MATE inhibitory ac-
tivity than the three first- generation agents. Furthermore, 
the most notable difference between palonosetron and the 
first- generation drugs is their affinity for 5- HT₃ receptors 
(~  10- fold lower inhibition constant values than those of 
ondansetron). In addition, the half- life is significantly in-
creased, to ~ 35 h compared with 5 h for the first- generation 
drugs. Therefore, the difference in pharmacokinetics can 
be attributed to a difference in elimination competition 
with cisplatin.
T A B L E  4  Patient characteristics of the overall series and propensity score matched pairs at baseline
Variable
Before propensity score matching After propensity score matching
1st (n = 126) 2nd (n = 305) p value 1st (n = 111) 2nd (n = 111)
p 
value
CIN incidence (%) 15 (11.9) 25 (8.2) 0.273 15 (13.5) 6 (5.4) 0.039
Sex (male/female) 92/34 238/67 0.264 83/28 85/26 0.876
Age (year) 61.0 (9.2) 63.6 (9.5) 0.009 61.5 (9.1) 63.0 (10.1) 0.247
Body weight (kg) 58.0 (11.6) 59.4 (11.4) 0.238 58.7 (11.7) 58.2 (11.8) 0.763
Height (cm) 162.3 (8.8) 163.7 (8.2) 0.112 162.5 (8.8) 162.5 (8.7) 0.999
BSA (m2) 1.61 (0.18) 1.64 (0.18) 0.149 1.62 (0.19) 1.61 (0.19) 0.815
Cisplatin dosing (mg/m2/
course)
78.2 [70.8– 79.9] 76.9 [70.0– 79.9] 0.650 78.2 [70.8– 79.9] 74.9 [68.8– 79.4] 0.826
eGFR (ml/min/1.73 m2) 84.4 [74.4– 97.4] 79.8 [70.6– 90.4] 0.001 83.3 [73.8– 96.5] 81.2 [73.6– 91.0] 0.475
Serum creatinine (mg/dl) 0.68 [0.59– 0.76] 0.73 [0.62– 0.84] 0.003 0.69 [0.60– 0.76] 0.72 [0.60– 0.78] 0.527
AST (IU/L) 23.0 (15.4) 24.4 (13.2) 0.343 23.9 (16.1) 23.2 (12.9) 0.754
ALT (IU/L) 21.5 (19.1) 21.8 (16.8) 0.903 22.5 (20.0) 21.4 (19.4) 0.678
Total bilirubin (mg/dl) 0.64 (0.29) 0.64 (0.25) 0.965 0.63 (0.29) 0.64 (0.26) 0.941
Serum albumin (g/dl) 3.4 (0.6) 3.6 (0.5) 0.012 3.4 (0.6) 3.5 (0.6) 0.504
Concomitant use of magnesium 
sulfate (%)
10 (7.9) 153 (50.2) <0.001 10 (9.0) 8 (7.2) 0.807
Comorbidities
Chronic heart disease (%) 0 (0.0) 7 (2.3) 0.112 0 0 NA
Hypertension (%) 26 (20.6) 65 (21.3) 1.000 24 (21.6) 25 (22.5) 1.000
Diabetes mellitus (%) 40 (31.8) 111 (36.4) 0.377 39 (35.1) 34 (30.6) 0.568
Note: Data are presented as mean (SD), median [interquartile range], or number of patients (%).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; CIN, cisplatin- induced nephrotoxicity; eGFR, estimated 
glomerular filtration rate; NA, not applicable.
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There were some limitations to this study. First, the 
results of the experiments conducted in cells and animals 
do not fully reflect the effect in humans. Second, the 
FAERS database accumulates spontaneous reports, which 
may be subject to bias such as under- or over- reporting. 
Therefore, we conducted a retrospective study using elec-
tronic medical records, which provide detailed patient 
information. The results suggest that the first- generation 
5- HT₃ receptor antagonists may increase the incidence of 
cisplatin- induced kidney injury. Our retrospective study 
using medical electronic records involved a small num-
ber of patients, and we could not obtain data about some 
potential factors of CIN, such as other antiemetics, other 
nephrotoxins, and hydration status. Additionally, palo-
nosetron is a more efficacious antiemetic than the first- 
generation 5- HT₃ receptor antagonists and, therefore, the 
hydration status may be improved. Consequently, our re-
sults may not be fully generalizable without further pro-
spective study in a larger population. Thus, although each 
method has its limitations, they can be overcome using 
multiple methods and information obtained through data-
bases. The results of basic experiments can be validated 
for drug efficacy using clinical data to predict clinical 
effects and safety. The results suggest that the concom-
itant use of first- generation 5- HT₃ receptor antagonists 
may be a risk factor for cisplatin- induced renal damage. 
However, second- generation 5- HT₃ receptor antagonists 
appeared to have less effect. Therefore, renal injury 
risk in high- risk patients may be reduced by selecting a 
second- generation 5- HT₃ receptor antagonist if the use of 
antiemetic agents is necessary.
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